Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
The objective of this current practice study was to explore the views and experiences of health care professionals and patients with atrial fibrillation regarding the use of warfarin and management of warfarin therapy for the prevention of thromboembolic events.
Contents
- 1. INTRODUCTION
- 2. BACKGROUND
- 3. ISSUE
- 4. OBJECTIVE
- 5. PROJECT OVERVIEW
- 6. METHODS
- 7. RESULTS
- 8. DISCUSSION
- REFERENCES
- APPENDIX A MODERATOR GUIDES
- APPENDIX B QUOTATIONS FROM MEDICAL SPECIALISTS
- APPENDIX C QUOTATIONS FROM GPS AND FAMILY PHYSICIANS
- APPENDIX D QUOTATIONS FROM ALLIED HEALTH PROFESSIONALS
- APPENDIX E QUOTATIONS FROM PATIENTS
This report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH).
This report is based on information on practice behaviours available at the time of report preparation and has not been reviewed by peers. The information in this report should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of the report to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this report.
CADTH takes sole responsibility for the final form and content of this report. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government.
Production of this report is made possible through a financial contribution from Health Canada.
- Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial Fibrillation
- Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Systematic Review of the Clinical Evidence
- Optimal Warfarin Management for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: Review of Canadian Economic Studies
- Recommendations for Optimal Warfarin Management for Prevention of Thromboembolic Events in Patients with Atrial Fibrillation
- NLM CatalogRelated NLM Catalog Entries
- Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?[JAMA. 2003]Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. JAMA. 2003 Nov 26; 290(20):2685-92.
- Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis.[Arch Intern Med. 1995]Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis.Middlekauff HR, Stevenson WG, Gornbein JA. Arch Intern Med. 1995 May 8; 155(9):913-20.
- Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).[J Am Coll Cardiol. 2014]Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, et al. J Am Coll Cardiol. 2014 Mar 25; 63(11):1082-7. Epub 2013 Nov 6.
- Review Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation.[Int J Cardiol. 2011]Review Alternatives to chronic warfarin therapy for the prevention of stroke in patients with atrial fibrillation.Lam YY, Ma TK, Yan BP. Int J Cardiol. 2011 Jul 1; 150(1):4-11. Epub 2010 Nov 26.
- Review Apixaban and atrial fibrillation: no clear advantage.[Prescrire Int. 2014]Review Apixaban and atrial fibrillation: no clear advantage.. Prescrire Int. 2014 Feb; 23(146):33-6.
- Warfarin Management in Patients with Atrial Fibrillation — Current Practice Stud...Warfarin Management in Patients with Atrial Fibrillation — Current Practice Study
- Internet-Delivered Cognitive Behavioural Therapy for Post-Traumatic Stress Disor...Internet-Delivered Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder: Recommendations
- HPV Testing for Primary Cervical Cancer Screening: A Health Technology Assessmen...HPV Testing for Primary Cervical Cancer Screening: A Health Technology Assessment
Your browsing activity is empty.
Activity recording is turned off.
See more...